This clinical trial is focused on studying the effects of a medication called dornase alfa on patients who have experienced a subarachnoid hemorrhage. A subarachnoid hemorrhage is a type of bleeding that occurs in the space around the brain, often due to a ruptured blood vessel. The treatment being tested involves the daily administration of dornase alfa through an intravenous (IV) infusion for up to 14 days following the hemorrhage.

The purpose of the study is to evaluate whether this treatment can improve the chances of patients achieving a good level of independence in their daily activities six months after the hemorrhage. Participants in the study will receive either the dornase alfa treatment or a placebo, and their progress will be monitored over time. The study aims to determine if the treatment can lead to better recovery outcomes compared to those who do not receive it.

Throughout the study, participants will undergo various assessments, including evaluations of their neurological function and brain imaging tests like MRI scans. These assessments will help researchers understand the impact of the treatment on the brain and overall recovery. The study will also track any side effects or complications that may arise during the treatment period. The ultimate goal is to see if dornase alfa can help improve recovery and quality of life for patients who have suffered a subarachnoid hemorrhage.